Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus

Abstract

Type 2 diabetes is characterized by decreased insulin secretion^1,2 and insulin sensitivity in liver, adipose tissue, and skeletal muscle. Together these abnormalities confound efforts to treat diabetes because most antidiabetic agents target only 1 underlying cause of the disease. Approximately 50% of patients treated with monotherapy require additional therapy to achieve target glycosylated hemoglobin (HbA_1c) levels 3 years after diagnosis.³